Data on trends in antimicrobial resistance and decreased susceptibility in gonococcal infection in England and Wales.
Ref: PHE publications gateway number: 2017465 PDF, 685KB, 24 pages
Ref: PHE publications gateway number: 2016433 PDF, 523KB, 45 pages
Ref: PHE publications gateway number 2015470 PDF, 966KB, 37 pages
Ref: PHE publications gateway number 2014442 PDF, 773KB, 33 pages
This file may not be suitable for users of assistive technology. Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email firstname.lastname@example.org. Please tell us what format you need. It will help us if you say what assistive technology you use.
Surveillance of antimicrobial resistance is critical in guiding national treatment guidelines to ensure appropriate patient management. The Gonococcal resistance to antimicrobial surveillance programme (GRASP) includes a suite of initiatives to detect and monitor antimicrobial resistance in N. gonorrhoeae and potential treatment failures.
Public Health England reports annually on drug resistance and decreased susceptibility in gonorrhoea in England and Wales and has twice provided data which directly influenced changes in treatment guidelines. The current treatment strategy in the UK (and in other countries) has been to adopt a more aggressive approach of dual therapy with injectable ceftriaxone and oral azithromycin.
Previous GRASP reports are available from the National Archives website.
Published: 30 October 2014
Updated: 17 October 2017
- Added 'GRASP report: data to June 2017'.
- Added ‘GRASP report: data up to October 2016’.
- Added ‘GRASP 2014 report’.
- First published.